Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Finance News Network Investor Event (December 2020)
12 slides from Alterity Therapeutics's conference presentation, Dec 2, 2020
Slide 1: Alterity Therapeutics
C ON F I DE NTI AL 1 Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) Geoffrey Kempler, CEO and Chairman December 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, o
Slide 3: Our Purpose
Our Purpose We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people with these diseases. CONFIDENTIAL 3
Slide 4: Year in Review
4 Allowance of US patent for next generation compounds to treat neurodegenerative diseases Raises $35M in placement to international and Australian institutions and sophisticated investors Commences enrolling Multiple System Atrophy patients in bioMUSE Study ATH 434 reduces α - synuclein pathology,
Slide 5: Parkinsonian Disorders: A Significant Unmet Need
Parkinsonian Disorders A Significant Unmet Need ▪ Parkinsonism is a syndrome of motor symptoms that includes slowness of movement, stiffness and tremor ▪ Major source of disability 5 M SA P a r ki nson ’ s Disease PSP ▪ Parkinsonian disorders also include atypical variants such as Multiple system
Slide 6: Excellent Progress with Lead Drug Candidate ATH434
Excellent Progress with Lead Drug Candidate ATH434 6 ▪ Robust efficacy in animal models of disease ▪ Evidence of neuroprotection with ATH434 treatment ▪ Findings corroborated in multiple labs ▪ Orphan Designation granted in US and EU in 2019 ▪ US Food and Drug Administration (FDA): 7 years of market
Slide 7: bioMUSE Natural History Study
bioMUSE Natural History Study • Design: Observational (no treatment) • Objective: De - risk Phase 2 study • Identify biomarker(s) suitable for endpoint in treatment study • Evaluate the change in biomarkers and clinical manifestations in patients with early MSA to track disease progression • Populat
Slide 8: Phase 2 Study Design
Phase 2 Study Design • Design: Randomized, double - blind, placebo controlled • Objectives • Assess target engagement and preliminary efficacy of ATH434 • Evaluate safety and tolerability of ATH434 • Population: Early MSA patients (parkinsonian variant) with motor symptoms ≤ 3 years • Sample size: 6
Slide 9: Market research on ATH434 in MSA
9 I 3 STRATEGY PARTNERS C O NFI D E NTI A L *Does not include spontaneous use in PD Severely debilitating, fatal illnesses with no current treatments are ripe for new entrants targeting what may be the actual cause of the disease. SUBSTANTIAL UNMET NEED Motivated by efficacy in treating the underlyi
Slide 10: Leadership of FDA Approvals in Neurology
Leadership of 3 FDA Approvals in Neurology David Stamler, M.D. Chief Medical Officer • 3 FDA Approvals in Neurology • Led FDA Advisory Committee and approval of Xenazine ® in Huntington’s disease in 2008 • Led clinical development and approval of Austedo ® in Huntington’s disease and Tardive dyskine
Slide 11: Investment Summary
Investment Summary x Targeting Orphan disease with no approved treatments • ATH434 has potential U.S. peak sales up to US$ 725 million x Development team with proven track record at FDA x Lead drug candidate ATH434 • Commenced natural history study to inform Phase 2 study • Completed Phase 1 with ex
Slide 12: For further information please contact
For further information please contact: info@alteritytherapeutics.com
Alterity Therapeutics — Finance News Network Investor Event (December 2020) on 6ix